- ASSOCIATE PROFESSOR Neuroscience
- ASSOCIATE PROFESSOR Pharmacology and Systems Therapeutics
- Gene Therapy
- Knockout Mice
- Membrane Proteins/Channels
- Molecular Biology
- Multiple Sclerosis
- Protein Complexes
- Signal Transduction
- Spinal Cord
- Synaptic Plasticity
- Systems Neuroscience
- Transcription Factors
- Transgenic Mice
- Visit Venetia Zachariou's Laboratory for more information.
- Signal transduction complexes in drug addiction
- Regulation of G protein signaling in stress and depression
- Novel intracellular targets for chronic pain treatment
- Epigenetic adaptations in chronic pain models
- Regulators of G protein signaling and obesity
Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone BJ, Tamminga CA, Nestler EJ, Zachariou V. Regulator of G protein signaling is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proceedings of the National Academy of Sciences of the United States of America 2013 May; 110(20).
Waugh JL, Celver J, Sharma M, Dufresne RL, Terzi D, Risch SC, Fairbrother WG, Neve RL, Kane JP, Malloy MJ, Pullinger CR, Gu HF, Tsatsanis C, Hamilton SP, Gold SJ, Zachariou V, Kovoor A. Association between regulator of G protein signaling 9-2 and body weight. PloS one 2011; 6(11).
Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V. R7BP modulates opiate analgesia and tolerance but not withdrawal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2012 Mar; 37(4): 1005-12.
Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, Zachariou V. A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. The Journal of neuroscience : the official journal of the Society for Neuroscience 2011 Apr; 31(15): 5617-24.
Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V. Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biological psychiatry 2010 Apr; 67(8): 761-9.
Traynor JR, Terzi D, Caldarone BJ, Zachariou V. RGS9-2: probing an intracellular modulator of behavior as a drug target. Trends in pharmacological sciences 2009 Mar; 30(3): 105-11.
Terzi D, Stergiou E, King SL, Zachariou V. Regulators of G protein signaling in neuropsychiatric disorders. Progress in molecular biology and translational science 2009; 86: 299-333.
Terzi D, Zachariou V. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnology journal 2008 Dec; 3(12): 1555-63.
Krishnan V, Graham A, Mazei-Robison MS, Lagace DC, Kim KS, Birnbaum S, Eisch AJ, Han PL, Storm DR, Zachariou V, Nestler EJ. Calcium-sensitive adenylyl cyclases in depression and anxiety: behavioral and biochemical consequences of isoform targeting. Biological psychiatry 2008 Aug; 64(4): 336-43.
Charlton JJ, Allen PB, Psifogeorgou K, Chakravarty S, Gomes I, Neve RL, Devi LA, Greengard P, Nestler EJ, Zachariou V. Multiple actions of spinophilin regulate mu opioid receptor function. Neuron 2008 Apr; 58(2): 238-47.
Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V. RGS9-2 is a negative modulator of mu-opioid receptor function. Journal of neurochemistry 2007 Oct; 103(2): 617-25.
McClung CA, Nestler EJ, Zachariou V. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005 Jun; 25(25): 205-11.
Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ. Essential role for RGS9 in opiate action. Proceedings of the National Academy of Sciences of the United States of America 2003 Nov; 100(23): 6005-15.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Zachariou did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 10 Room 10-20B
1425 Madison Avenue
New York, NY 10029
Icahn Medical Institute Floor 10 Room 02 (Lab)
1425 Madison Avenue
New York, NY 10029